Introduction
Initial enthusiasm to explore gene expression profi ling and other high-throughput molecular methods as molecular diagnostic tools for breast cancer has given way to increasing skepticism. Several investigators suggested that these novel analytical methods may not have advanced diagnostic medicine beyond what optimally performed histology and immonohistochemistry (IHC) could deliver. Th ere is some truth in this criticism, particularly when it comes to clinically useful assays that gene expression profi ling methods have yielded. However, this overly simplistic assessment of molecular profi ling overlooks three important contributions that high-throughput gene expression analysis has brought to breast cancer research and treatment. First, results from gene expression profi ling studies have fundamentally changed our conceptual approach to breast cancer. Second, these methods have yielded several commercially available new diagnostic tests that fi ll a previously unmet diagnostic niche and have started to impact routine care, at least in the United States. Th ird, the impact of the large volume of molecular data that these studies have generated will have a lasting impact on breast cancer research. Th e in-depth analysis of the many tantalizing observations made from comprehensive genomic characterization of breast cancers has barely begun.
The conceptual impact of molecular profi ling on breast cancer research
Gene expression profi ling provided the fi rst glimpse of the true complexity of the molecular machinery of breast cancer. Th e earliest of these studies already revealed large-scale molecular diff erences between estrogen receptor (ER)-positive and ER-negative cancers and also revealed two robust subsets within the ER-positive cancers [1] . Th ese molecular diff erences between breast cancer subsets together with the important clinical diff erences that also distinguish these groups have prompted a conceptual shift in the classifi cation of breast cancer. Breast cancer is no longer considered a single disease with variable ER expression, histology and grade but a collection of genuinely diff erent neoplastic diseases that arise from the breast epithelium. Th e long recognized heterogeneity in ER expression and grade have not led to similar shifts in classifi cation in the past because the scale of molecular diff erences that exist between these disease types remained hidden until highthroughput molecular analytical methods become available. Th e implications of the new classifi cation schema reach far beyond a simple ER-based stratifi cation of breast cancer. Diff erent molecular types of breast cancers will require separate clinical trials, diff erent prognostic and predictive markers and diff erent therapeutic strategies. Continued conduct of studies that include all types of breast cancers is akin to conducting a trial for leukemia where patients with acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and so on, are all eligible for participation. Results from such studies would be unstable and have limited practical value considering the vast clinical and molecular diff erences between these diff erent types of leukemias. Indeed, the next generation of thera peutic and biomarker studies in breast cancer are increasingly being targeted to molecularly defi ned subsets such as triple-negative/basal-like or ER-positive high risk (Luminal A or MammaPrint or Oncotype Dx high risk groups) breast cancers.
The impact of molecular profi ling on molecular diagnostics
Molecular profi ling simultaneously measures a large number of variables (that is, gene expression values, DNA copy numbers or single nucleotide polymorphisms) and the simplest goal of the analysis is to fi nd individual variables that are associated with a disease subset or clinical outcome group. Th is analysis strategy brought into focus two very important statistical concepts, long neglected in traditional biomarker research: the importance of combining individual, independent markers into multivariate prediction models; and the need to guard against false discovery due to multiple comparisons. Invariably, more than one marker is associated with any particular out come or disease subset. Historically, markers were used as stratifi cation tools and classifi cation schemas were either restricted to a single marker (that is, groups were defi ned as marker high versus marker low) or multiple markers were used as sequential stratifi cation tools. However, subsetting of patients through multiple layers of dichotomous markers is not practical and leads to unstable results due to the rapidly diminishing numbers in the subsets. Th e statistically optimal use of indepen dent variables is to construct a multivariate prediction model. Despite close to four decades of IHC literature, very few papers describe correctly trained and indepen dently validated multivariate prediction models. Th is has started to change lately, due to the impact of molecular profi ling studies, and will undoubtedly increase the value of IHC-based tests through combining multiple diff erent IHC markers into more powerful prediction models.
Molecular profi ling also brought into the forefront the importance of guarding against false positive discoveries due to multiple comparisons. When only a single marker is assessed and a 5% signifi cance level is applied to the statistical test, there is only a 5% chance of incorrectly rejecting the null hypothesis (that is, lack of association between a marker and an outcome) if the null hypothesis is correct. However, if one performs 100 independent tests where all null hypotheses are correct, the expected number of false positive fi ndings is 5. Th e probability of fi nding at least one positive association among the 100 tests is virtually 100% even if none of the markers is associated with the endpoint. Historically, IHC studies often evaluated multiple diff erent markers and the same marker may have been correlated with several diff erent endpoints, yet adjustments for the multiple hypothesis testing were rarely performed. More recently, investigators and journal editors started to require such adjustments even in 'low throughput' multiple compari son studies, which will raise the level of evidence that these analyses produce.
Perhaps the most important practical contribution of genomics to breast cancer management was the development of multi-gene assays (Oncotype Dx, MammaPrint, Genomic Grade Index) that can distinguish low and high risk prognostic groups among ER-positive, early stage breast cancers [2, 3] . In the past, selection of adjuvant chemotherapy for ER-positive cancers was based on tumor size, nodal status, histologic grade, patient preference, and comorbid illnesses. However, none of these variables, with the exception of grade, has a consistent association with sensitivity to chemotherapy or endocrine therapy. Combination of these variables into a summary recommendation about therapy is subjective and frequently leads to variable recommendations by diff erent physicians. Multivariate genomic assays that take input from ER and human epidermal growth factor receptor 2 (HER2) expression as well as from a number of proliferation-related genes can stratify ER-positive cancers into low and high risk prognostic groups objectively and this information is additive or complementary to prognostic risk based on tumor size and nodal status. Th ese assay results can also inform about general chemotherapy sensitivity [4, 5] . It has also become apparent that the most important prognostic and predictive component of these fi rst generation assays comes from their ability to measure proliferation reproducibly and quantitatively [6] . Hence, simpler proliferation measurements may accomplish the same. However, an important feature of these commercially available tests is that they are standardized and validated in multiple independent studies. Multi-IHC tests, including ER, progesterone receptor, HER2, Ki67 (and other genes) may accomplish similar risk stratifi cation in the future but, currently, despite over 25 years of research, no standardized and externally validated IHCbased risk stratifi cation assay exists for breast cancer.
Future potential
Molecular profi ling is uniquely suited for multiplex assays. A single assay from one needle biopsy specimen can generate a large number of data points. A variable assortment of diff erent genes (or other molecular variable) can be used to issue simultaneously several diff erent prognostic or predictive results. Th e cost of gene expression analysis has dropped substantially over the past few years and the analytical validity of the diff erent platforms is well established [7, 8] . Gene expression results and other molecular readouts are quantitative over a relatively broad dynamic range and can easily be fed into standardized computer prediction algorithms. On the other hand, multiplex IHC assays are cumbersome to perform and the quantifi cation of the signal is still not standardized across pathology laboratories. It is hard to imagine that one could perform more than a few multi-IHC tests on the same case if each tests relies on measuring four to six diff erent antigenes that require individual sections and separate scoring. Combin ing the individual IHC results into several diff erent multi-IHC scores is not well suited for automation and could be error prone if performed by humans. Th e future of molecular profi ling as a diagnostic tool will depend to a large extent on the content that can be generated by these platforms. If new and clinically useful, validated predictive signatures can be developed, molecular profi ling has a bright future as diagnostic technology. Th e more such signatures exist, the greater the utility of a high-throughput, standardized, easily automated platform.
Finally, the impact of the large volumes of public data that molecular profi ling studies have generated cannot be compared with the impact of IHC studies that measure the expression of one or a handful of genes [9] . Th e indepth analysis of the many tantalizing observations made from comprehensive genomic characterization of breast cancers has barely begun and may ultimately represent the most important future contribution of molecular profi ling to cancer research.
